WO2004087764A1 - ダイオキシンを認識する組換抗体および該抗体をコードする遺伝子 - Google Patents
ダイオキシンを認識する組換抗体および該抗体をコードする遺伝子 Download PDFInfo
- Publication number
- WO2004087764A1 WO2004087764A1 PCT/JP2004/004355 JP2004004355W WO2004087764A1 WO 2004087764 A1 WO2004087764 A1 WO 2004087764A1 JP 2004004355 W JP2004004355 W JP 2004004355W WO 2004087764 A1 WO2004087764 A1 WO 2004087764A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- polypeptide
- acid sequence
- variable region
- seq
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
Definitions
- the present invention relates to a novel recombinant antibody having binding activity to 2,3,4,7,8-pentachlorodibenzofuran (2,3,4,7,8-PeCDF), which encodes its amino acid sequence.
- Gene a vector into which the gene has been introduced, a transformant transformed with the vector, a method for producing the recombinant antibody, and immunization of 2, 3, 4, 7, 8-Pe CDF using the recombinant antibody It relates to biological capture and measurement methods.
- Dioxins include a number of structural isomers consisting of 75 polychlorodibenzodioxins (PCDDs) and 135 polychlorodibenzofurans (PCDFs).
- PCDDs polychlorodibenzodioxins
- PCDFs polychlorodibenzofurans
- T EQ dioxin amount
- Japanese Patent Application Laid-Open No. 2002-340882 discloses that dioxins are collected using a dioxin collection unit, an extraction unit, a separation and purification unit, and an antibody. A measuring device and a measuring method for dioxins composed of four measuring units are described.
- Japanese Patent Application Laid-Open No. 2002-228660 discloses that dioxins in biological samples such as human blood and breast milk are prepared by using monoclonal antibodies having high affinity to 2,3,7,8-TCDD. Are described.
- Japanese Patent Application Laid-Open No. 2002-119279 describes a method for estimating the abundance of dioxins by using several kinds of antibodies having cross-reactivity to a plurality of dioxins isomers.
- these documents include a monoclonal antibody recognizing 2,3,4,7,8_Pe CDF, a gene sequence encoding the monoclonal antibody, a recombinant antibody based on the gene sequence, and a recombinant antibody based on the gene sequence.
- the method for measuring 2, 3, 4, 7, 8-P e CDF using a recombinant antibody is not described.
- the present inventors have determined that the 17 major dioxins measured by the HRGC / HRMS method are the major constituents, and that the content of the dioxins is an indicator isomer having a high correlation with the total TEQ of the dioxins. , 3, 4, 7, and 8-Pe CDF by immunological techniques were sought to establish a rapid, simple, and sensitive method for capturing and measuring.
- the present inventors have solved the above-mentioned problems by using a 2,3,4,7,8-Pe CDF derivative as an antigen and carrying out 2,3,4,7, Two hybridomas producing monoclonal antibodies that recognize 8_P e CDF, namely, hybridoma DX 3860 r1 producing monoclonal antibody DX3860 and hybridoma D3150 r1 producing monoclonal antibody D3150 Obtained.
- the present inventors isolated and isolated mRNA contained in these hybridomas. And purified, and cDNA was synthesized based on the mRNA. Next, from the cDNA, the H chain variable region and the L chain variable region of the monoclonal antibody DX380 are encoded, and the H chain variable region and the L chain variable region of the monoclonal antibody DX3150 are encoded. In order to select cDNA, PCR was performed using a sequence specific to the antibody gene to specifically amplify the target antibody gene. The nucleotide sequences of these selected cDNAs were analyzed, and the amino acid sequences encoded by them were deduced.
- the cDNAs encoding the H chain variable region and the L chain variable region of the monoclonal antibody DX3680 are shown in SEQ ID NOs: 1 and 2, respectively, while the monoclonal antibody DX315
- the cDNAs encoding the H chain variable region and the L chain variable region of 0 were found to be represented by SEQ ID NOS: 3 and 4, respectively.
- the deduced amino acid sequences of the H chain variable region and the L chain variable region of the monoclonal antibody DX380 are shown in SEQ ID NOS: 5 and 6, respectively, while the H chain variable region of the monoclonal antibody DX3150 is The putative amino acid sequences of the region and the light chain variable region were found to be shown in SEQ ID NOs: 7 and 8, respectively.
- the present inventors specified the amino acid sequence of the hypervariable region (CDR 1-3) in the variable region of the antibody and the position thereof.
- the amino acid sequences of the hypervariable regions are shown in Tables 1-4 below.
- Table 1 Amino acid sequence of the hypervariable region in the variable region of Dx3680 H chain
- the positions of the hypervariable regions (CDRs 1 to 3) in the H chain and L chain variable regions of the monoclonal antibody DX3860 are shown in FIGS. 1 and 2 together with the DNA sequence and amino acid sequence, respectively.
- the positions of the hypervariable regions (CDRs 1 to 3) in the variable regions of the H and L chains of the monoclonal antibody DX3150 are shown in Figs. 3 and 4 together with the DNA sequence and the amino acid sequence. .
- positions 26 to 33 of the amino acid sequence represent CDR1
- CDRs 51 to 57 represent CDR2
- positions 96 to 103 represent CDR3.
- positions 26 to 34 of the amino acid sequence are CDR1
- positions 52 to 54 are C
- positions 26 to 34 of the amino acid sequence indicate CDR1
- CDRs 52 to 58 indicate CDR2
- positions 97 to 107 indicate CDR3.
- positions 26 to 34 of the amino acid sequence indicate CDR1
- positions 52 to 54 indicate ⁇ DR2
- positions 91 to 99 indicate CDR3.
- the present inventors incorporated DNA encoding the variable region of the above antibody into an expression vector, introduced the vector into a host cell, and expressed the recombinant antibody in the host cell. Furthermore, the present inventors have confirmed that 2,3,4,7,8-PeCDF in a sample can be quantified using the recombinant antibody. Further, the present inventors introduced a mutation into DNA encoding the variable region of the above antibody, expressed the recombinant antibody using the mutated DNA as described above, and using the recombinant antibody, 2, 3, 4, 7, 8- It was confirmed that P e CDF could be quantified.
- the present invention relates to a recombinant antibody having binding activity to 2,3,4,7,8-pentachlorodibenzofuran (2,3,4,7,8-P e CDF),
- polypeptide comprising an H chain variable region of a monoclonal antibody Dx3860 that recognizes 2, 3, 4, 7, 8-PeCDF and having an amino acid sequence represented by SEQ ID NO: 5;
- polypeptide comprising an H chain variable region of a monoclonal antibody Dx3150 that recognizes 2, 3, 4, 7, 8-PeCDF and having an amino acid sequence represented by SEQ ID NO: 7;
- a recombinant antibody comprising at least one polypeptide selected from the group consisting of:
- the present invention provides a DNA encoding the amino acid sequence of the above-mentioned recombinant antibody, a cloning or expression vector containing the DNA, a transformant transformed with the vector, And a method of immunologically capturing and measuring 2,3,4,7,8-PeCDF using the recombinant antibody. is there.
- dioxins particularly 2,3,4,7,8-PeCDF
- Using the recombinant antibody of the present invention dioxins, particularly 2,3,4,7,8-PeCDF, can be rapidly and simply and highly sensitively captured and measured by immunological techniques. Cut. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 shows the positions of the DNA sequence, amino acid sequence and hypervariable region (CDR 1-3) of the variable region of the H chain of the monoclonal antibody DX3860.
- FIG. 2 shows the positions of the DNA sequence, amino acid sequence, and hypervariable regions (CDR 1-3) of the light chain variable region of monoclonal antibody DX3860.
- FIG. 3 shows the positions of the DNA sequence, amino acid sequence and hypervariable region (CDR 1-3) of the H chain variable region of the monoclonal antibody DX3150.
- FIG. 4 shows the positions of the DNA sequence, amino acid sequence and hypervariable regions (CDR 1-3) of the light chain variable region of the monoclonal antibody DX3150.
- FIG. 5 shows the construction of the scFV fragment Dx 386 OHL.
- FIG. 6 shows the construction of the scFV fragment DX3860 LH.
- FIG. 7 shows the configuration of the sc Fv fragment Dx3150HL.
- FIG. 8 shows the configuration of the scFV fragment Dx3150 LH.
- FIG. 9 shows the results of measuring 2, 3, 4, 7, 8-PeCDF by indirect competitive immunoassay using anti 2,3,4,7,8-PeCDF scFv. It is a graph.
- FIG. 10 is a graph showing the relationship between the H chain variable region polypeptide fraction and the activity of anti-2, 3, 4, 7, 8-Pe CDF.
- FIG. 11 shows the amino acid sequence of the V H chain mutant of the monoclonal antibody DX3860.
- FIG. 12 shows that the mutated D X 3860 scFv-displaying phage showed 2, 3, 4, 7,
- FIG. 13 is a graph comparing the antibody titers of mutated D X 3860 scFv-displaying phage.
- FIG. 14 is a graph comparing the reactivity of mutated Dx3860 scFV-displaying phage in the presence of DMSO.
- the “antibody” referred to in the present invention includes, in addition to a naturally-occurring antibody present in a living body, at least one of a variable region of an H chain or an L chain of the antibody or a combination thereof Polypeptides having an antigen binding site are included. Such polypeptides include, for example, polypeptides containing only the H or L chain variable region, Fab fragments consisting of one set of H chain fragments and L chains, and two sets of H chain fragments and L chains. F (ab ') 2 fragment comprising a chain; a single-chain recombinant antibody (scFV) in which an H-chain variable region and an L-chain variable region are linked together by a linker;
- scFV single-chain recombinant antibody
- the linker is arranged between the H chain variable region and the L chain variable region so that the F chain variable region is efficiently folded when the sc FV binds to the antigen.
- the linker is usually are composed of 5 to 1 5 amino acids, for example, - (G ly 4 S er ) 3 - can be mentioned as an example.
- the linker used in the present invention is not limited in the number and type of amino acids as long as the above object can be achieved.
- an appropriate amino acid sequence may be further added to the N-terminal side and the C-terminal side of the H-chain variable region or the L-chain variable region.
- an appropriate amino acid sequence may be further added to the N-terminal side and the C-terminal side of the H-chain variable region or the L-chain variable region.
- the polypeptide is secreted to the N-terminal side of the H chain variable region.
- An epitope tag sequence can be added to the signal region at the C-terminal side of the L chain variable region.
- a secretory signal region is placed on the N-terminal side of the L chain variable region, and a C-terminal side of the H chain variable region.
- An epitope tag sequence can be added to the tag.
- the recombinant antibody of the present invention includes, in addition to a polypeptide having at least one antigen-binding site formed by the variable region of the H or L chain of the antibody or a combination thereof, substantially the same as these polypeptides Mutant polypeptides having functions are included.
- substantially the same function as used in the present invention means that the binding ability to an antigen is substantially the same. That is, the variable region of the H chain and the L chain of the anti-2,3,4,7,8-Pe CDF antibody of the present invention having the amino acid sequences represented by SEQ ID NOS: 5 to 8 has an antigen-binding ability.
- Such a mutant polypeptide of the present invention has a homology of preferably 95% or more, more preferably 98% or more, and most preferably 99% or more with the amino acid sequences represented by SEQ ID NOS: 5 to 8. Further, this mutation is preferably present in a framework other than the hypervariable regions (CDRs 1-3) in the antibody variable regions shown in FIGS.
- the recombinant antibody of the present invention includes a fragment of the polypeptide represented by SEQ ID NOS: 5 to 8, which has substantially the same function as the original polypeptide, and a combination of these fragments. Includes the polypeptides formed. These fragments contain at least one, preferably two, and more preferably all three of the hypervariable regions (CDRs 1-3) shown in FIGS.
- the recombinant antibody of the present invention comprises preparing a DNA encoding the amino acid sequence of a desired polypeptide, incorporating the DNA into an expression vector, introducing the expression vector into a host cell, and placing the host cell in an appropriate medium.
- the recombinant antibody can be produced by culturing the recombinant antibody.
- DNA encoding the amino acid sequence of the desired polypeptide can be prepared synthetically based on the cDNA or amino acid sequence shown in SEQ ID NOs: 1-4 (or FIGS. 1-4).
- a DNA encoding the amino acid sequence of a desired polypeptide can be obtained as follows. That is, as shown in the following examples, the present inventors have proposed a fragment containing the H chain variable region of the monoclonal antibody DX3860, the linker, and the L chain variable region of Dx3860 in this order from the N-terminal side (see FIG. This vector was introduced into Escherichia coli B, and the Escherichia coli B (pET22 ⁇ -Dx3860HL) was deposited at the Patent Biotechnology Deposit Center.
- the present inventors incorporated a fragment (see FIG. 7) containing, in this order, the H chain variable region of the monoclonal antibody DX3150, the linker, and the L chain variable region of DX3150 from the N-terminal side.
- An expression vector was prepared, this vector was introduced into E. coli K-12, and this E. coli K-12 (pET22 ⁇ -DX3
- DNA encoding the amino acid sequence of the desired polypeptide can be obtained by cutting out these expression vectors using an appropriate restriction enzyme and, if desired, mutating the DNA sequence.
- the ends of the fragment are modified in the usual manner. Can be decorated.
- Incorporation of the obtained DNA fragment into an expression vector is performed by matching the DNA fragment with a predetermined fragment insertion site of a commercially available expression vector [eg, pET-22b (+)]. It can be carried out by processing the ends and inserting the DNA fragments whose ends have been processed into an expression vector.
- a commercially available expression vector eg, pET-22b (+)
- the expression vector thus obtained is introduced into a suitable host cell, particularly Escherichia coli [eg, Escherichia coli B strain, K-12 strain, BL21 (DE3) strain, etc.], and the inserted DNA fragment is inserted into the DNA fragment.
- Escherichia coli eg, Escherichia coli B strain, K-12 strain, BL21 (DE3) strain, etc.
- the desired recombinant antibody By culturing the host cell in a medium suitable for expression, the desired recombinant antibody can be expressed.
- the expressed recombinant antibody can be recovered from the host cell or its culture solution by a conventional method.
- the recovered recombinant antibody can be purified by, for example, one method of mouth chromatography.
- a desired recombinant antibody can be produced at a lower cost and in a larger amount than a monoclonal antibody obtained by culturing animal cells in a medium requiring serum.
- 2,3,4,7,8-P e CDF in a sample can be captured quickly and immunologically.
- capture methods include immunochromatographic and immunoprecipitation methods for the separation, purification and enrichment of 2,3,4,7,8-Pe CDF.
- the main substance among the dioxins ingested into the living body using the recombinant antibody is 2,2,4,7,8-Pe CDF.
- 3,4,7,8-Pe CDF can be quickly captured and removed.
- 2,3,4,7,8_P e CDF in a sample can be measured immunologically quickly and with high sensitivity using the obtained recombinant antibody.
- assays include radioimmunoassay (RIA), enzyme immunoassay (EIA), and fluorescence immunoassay (FIA).
- Immunoassays are broadly divided into noncompetitive and competitive methods.
- the recombinant antibody of the present invention is preferably used in a competition method. These competition methods include indirect and direct competition methods.
- 2,3,4,7,8-Pe CDF derivative is immobilized, and free 2,3,4,7,8_P e CDF in the sample is immobilized on the immobilized antigen. With recombinant antibodies Compete the reactions.
- the direct competition method the recombinant antibody is immobilized, and depending on the amount of 2,3,4,7,8-Pe CDF present in the sample, the label 2,3,4 that binds to the recombinant antibody is used. The amount of 7,7-P e CDF derivative is determined.
- a hybridoma producing a monoclonal antibody recognizing 2, 3, 4, 7, 8-PeCDF was prepared as follows. That is, first, an alkyl chain was introduced into 2,3,4,7,8_PeCDF, and its terminal was used as an active ester. Then, this was introduced into carrier serum albumin (BSA), which is a carrier protein, according to a conventional method to prepare a conjugate for immunization.
- BSA carrier serum albumin
- This conjugate for immunization was sufficiently emulsified in the adjuvant RAS R-700 (Ribi), and 200 ⁇ l of this iridium was administered intraperitoneally to BALB / c mice (7 weeks old, female). Mice were immunized. Booster immunizations were performed every two weeks, and approximately one week after the booster immunization, blood was collected from the tail vein and the antibody titer in the blood was measured by the competitive EIA method.
- mice with high antibody production against 2, 3, 4, 7, 8-Pe CDF were selected, and a immunization conjugate was administered into the tail vein for final immunization.
- the spleen was excised and spleen cells were prepared.
- Mouse myeoma cells (Sp 2 ZO) in the logarithmic growth phase and spleen cells were mixed so that the number of cells became 1: 5, and cell fusion was performed by the polyethylene dalicol method (PEG method).
- PEG method polyethylene dalicol method
- a substrate solution (TMB substrate, KPL) was added, the peroxidase activity on the plate was measured, and the antibody titer in the culture supernatant was determined.
- the antibody titer against the immobilized 2,3,4,7,8-Pe CDF derivative-BSA conjugate was 2,3,4,7,20% dissolved in DMSO.
- a well that was greatly inhibited by 8-Pe CDF was selected, and the hybridoma in the well was cloned by the limiting dilution method.
- cDNA was synthesized from poly (A) + RNA of the above g.
- the obtained cDNA was designated as type ⁇ , and Mouse Ig-Primer Set (Novagen) and Taq DNA polymerase (Applied
- PCR was performed using Biosystems). MuIg VH5'-A and MuIgVH3'-2 primer set for Dx3860 H chain, MuIg VH5'-D and MuIg VH3'-2 primer set for Dx315 OH chain A set was used. Also, both Dx3 860 L chain and Dx3150 L chain have Mu Ig V L 5'-A and Mu I g V L 3, - using one of the primer sets. The primers used are shown in Table 5 below. The PCR reaction was performed as follows.
- MuIgVH3'-2 CCCAAGCTTCCAGGGRCCARKGGATARACIGRTGG (SEQ ID NO: 23)
- the PCR product was inserted into pGEM-T Easy using a TA cloning kit, pGEM-T Easy Vector System I (Promega), and then E. coli XL1-B1ue was transformed. XL1-Blue Competent Cells (STRATAGENE) were used as the competent cells.
- the sequence was analyzed by Analyzer (Applied Biosystems). As a result, the nucleotide sequence of cDNA encoding the variable regions of the H and L chains of the Dx3860 antibody gene and its deduced amino acid sequence (SEQ ID NOS: 1 and 2), and the H sequence and L sequence of the DX3150 antibody gene
- SEQ ID NOS: 3 and 4 The nucleotide sequence of cDNA encoding the chain variable region and its deduced amino acid sequence (SEQ ID NOS: 3 and 4) were obtained.
- the analysis software DNAsis was used for the estimation and analysis of the amino acid sequence.
- the hypervariable regions contained in the sequences of SEQ ID NOs: 1 to 4 were identified according to the classification of the ImMunoGeneTics database (http: @imgt. Cines. Fr). This database is based on Lefranc, ⁇ ⁇ -P. Et al. [Nucleic Acids Research, 27, p.209-212 (1999)],
- CDRs 1-3 The locations of the identified hypervariable regions (CDRs 1-3) are shown in FIGS. 1-4 along with the DNA and amino acid sequences.
- the cDNA of the H chain and the L chain of the cleaved antibody gene are linked by a DNA encoding a linker sequence, and a restriction enzyme is used to incorporate this into an expression vector.
- the primer containing the sequence the cDNA of the H chain and the L chain was amplified by PCR.
- For the Dx315 OH chain change the sequence of the BamHI site from GGATCC to GGATTC, and design primers to include the sequence before and after the BamHI site. And amplified.
- the linker DNA was amplified by PCR using primers containing a part of these sequences to ligate the H chain and L chain cDNAs by fill-in.
- Linker-5 (3860H) GGT ACC CTG GTC ACT GTC TCT TCC GGA GGA GGC GGT TCA G (SEQ ID NO: 32)
- Linker-3 (3860L) AGA TTC CTG AGT CAC AAC AGC CTG GGA TCC GCC ACC GCC AG (SEQ ID NO: 33 )
- PCR amplification was performed as follows using rAq DNA polymerase (Toyobo) using GeneAmp PCR System 9700 (Applied Biosystems). That is, a reaction cycle of 94 ° CXI min, 58 ° CXI min, and 72 ° CX for 1 min was performed in 5 cycles, and further, 94 ° CX for 1 min, 48 ° CX for 1 min, and 72 ° CX A 1 minute reaction cycle was performed for 20 cycles. After PCR amplification, each PCR product was separated by 3% agarose gel electrophoresis. Cut out gel containing DNA fragment and extract DNA from gel using MagExtractor -PCR & Gel Clean Up- (Toyobo) did.
- FIGS. 5-8 SEQ ID NOs: 56-59; only the amino acid sequence is SEQ ID NOs: 60-63).
- Figure 5 shows a sc FV fragment (Dx3860HL) that contains, in this order, the H chain variable region of the monoclonal antibody DX3860, the linker, and the DX3860 L chain variable region from the N-terminal side. Positions 1-114 of the amino acid sequence represent the H chain variable region, positions 115-129 represent the linker, and positions 130-239 represent the L chain variable region.
- Figure 6 shows a sc FV fragment (DX 3860 LH) that includes, in this order, the L chain variable region of the monoclonal antibody DX 3860, the linker, and the H chain variable region of DX 3860 from the N-terminal side.
- positions 1-110 of the amino acid sequence represent the L chain variable region
- positions 112-126 represent the linker
- positions 127-240 represent the H chain variable region.
- Figure 7 shows a scFV fragment (Dx315OHL) containing, in this order, the H chain variable region of the monoclonal antibody DX3150, the linker, and the DX3150 L chain variable region from the N-terminal side.
- positions 1-118 represent the H chain variable region
- positions 119-133 represent the linker
- positions 134-243 represent the L chain variable region.
- FIG. 8 shows a sc FV fragment (Dx3150 LH) containing, in this order, the L chain variable region of monoclonal antibody Dx3150, the linker, and the H chain variable region of Dx3150 from the N-terminal side.
- positions 1-110 represent the L chain variable region
- 112-126 represent the linker
- 127-244 represent the H chain variable region.
- PCR was performed by adding primers corresponding to both ends (NcoI-NotI) of scFV to the reaction solution.
- a reaction cycle of 2 ° CX for 1 minute and 75 ° CX for 4 minutes was performed for 5 cycles, and a further 20 cycles of 95 ° CX for 1 minute, 55 ° CX for 1 minute, and 75 ° CX for 4 minutes were performed. .
- the PCR product was separated by 1.5% agarose gel electrophoresis, the gel containing the scFv DNA fragment (730-740 bp) was cut out, and the DNA fragment was extracted from the gel. Then, the end of this DNA fragment was treated with restriction enzymes NcoI (New England BioLabs) and NotI (Toyobo) and purified again by MagExtractor.
- the scFV DNA fragment was inserted into the NcoI-NotI site of the expression vector pET22 ⁇ , and E. coli XL1-B1ue was transformed with this expression vector.
- E. coli XL1-B1ue was transformed with this expression vector.
- DNA Ligetion Kit Ver.2 (Takara Shuzo) was used, and XL Competent Blue Competent Cells (STRATAGENE) were used as competent cells.
- STRATAGENE XL Competent Blue Competent Cells
- the expression vector pET22 ⁇ -Dx3860HL was introduced into Escherichia coli B and transformed into Escherichia coli B (pET22 ⁇ -DX380HL). 3150HL was introduced into Escherichia coli K-12 and transformed into Escherichia coli K-12 (pET22 ⁇ -DX3150HL) on February 27, 2003 Deposited with the Patent Organism Depositary of the National Research Institute, and obtained accession numbers F ERM BP-8305 and FERM BP-830, respectively.
- sc FV fragment DX3860 Expression vector with HL integrated pET22 Escherichia coli Origami B (DE3) (Novagen) transformed with UM-Dx386 OHL is cultured at 37 ° C in 300 ml of LB medium until 6D600 becomes about 0.5. did. Then, the culture temperature was lowered to 25 ° C, and the culture was continued. When the OD600 reached about 1.0, IPTG (isopropylthiogalactoside) was added to the mixture so that the final concentration became 1 mM, and the cells were cultured overnight to induce the expression of scFV.
- IPTG isopropylthiogalactoside
- the cells After collecting about 1 g of the cells by centrifugation, the cells were suspended in 5 OmM Tris-HC1 (pH 8.0), 0.1 MNaCl, and lysozyme (final concentration: 0.2 mg / m1) And Triton X_100 (final concentration 1%) were added for lysis. Collect the precipitate by centrifugation (15,000 Xg, 20 minutes), wash the precipitate twice with a buffer containing 1.0% Triton X-100, and wash the precipitate containing scFv with approx. 0 mg was obtained.
- ScFV obtained as inclusion bodies were added in a buffer of 25 mM PB, 350 mM NaC1, 6 M guanidine'HC1 (pH 7.4). C was left standing overnight to dissolve. After removing the residue by centrifugation (10,000 X g, 15 minutes), the mixture was applied to a -chelchel chelate column (Qiagen) equilibrated with the above buffer. After thoroughly washing the buffer with about 5 to 10 times the volume of the buffer, the buffer was replaced with the above buffer containing 20% glycerol and 400 mM arginine. The scFV bound on the chelating column was reconstituted using a gradient of guanidine'HC1 from 6 M to 0 M.
- H chain variable region polypeptide Restriction enzyme containing L chain variable region of expression vector pET22 2 ⁇ -D x 3860 HL Escherichia coli Origami B (DE3) (Novagen) was transformed using the expression vector pET22-DX380H produced by removing the sequence between the sites BamHI-NotI. Using this transformant, H chain variable region polypeptide (polypeptide having an amino acid sequence represented by SEQ ID NO: 5) was expressed in the same manner as scFV.
- the H chain variable region polypeptide obtained as an inclusion body was reconstituted on a nickel 'chelate column in the same manner as described above, and then isolated and purified using imidazole.
- the protein concentration was determined by measuring the absorbance (280 rim) of the fraction eluted from the chelate column, and the solid-phased 2, 3, 4, 7, 8-Pe
- the cells were collected by centrifugation, resuspended in 10 ml of 2 XYT medium containing 100 ⁇ g / m1 ampicillin and 50 ⁇ g / m1 kanamycin, and cultured overnight at 37 ° C. Single-chain antibody display phage were produced.
- the culture solution was centrifuged, and 2 ml of a 20% polyethylene glycol solution containing 2.5 M NaC1 was added to 1 ml of the culture supernatant from which E. coli cells had been removed, and mixed. After leaving it on ice for 1 hour, it was centrifuged (10000 g x 20 minutes) under cooling. After the supernatant was completely removed, the resulting precipitate was dissolved in 1 ml of a 10-fold diluted Block Ace (Snow Brand) to obtain a single-chain antibody-displayed phage solution.
- a 20% polyethylene glycol solution containing 2.5 M NaC1 was added to 1 ml of the culture supernatant from which E. coli cells had been removed, and mixed. After leaving it on ice for 1 hour, it was centrifuged (10000 g x 20 minutes) under cooling. After the supernatant was completely removed, the resulting precipitate was dissolved in 1 ml of a 10-fold diluted Block Ace (Snow Brand) to obtain a
- the plate was transferred to a plate (100 ⁇ l / Pell) and reacted at room temperature for 1 hour in the presence of 8% DMS. After the reaction, add 300 ⁇ l of PBS containing 8% DMS O and 0.1% Tween 20 to each well of the plate.
- M13K ⁇ 7 phage was added to a culture solution containing ampicillin (final concentration 100 ⁇ g / ml) and glucose (final concentration 2%) to a final concentration of 4 ⁇ 10 9 pfu / ml, and then incubated at 37 ° C. The cells were cultured at C for 1 hour.
- the cells were resuspended in 10 ml of 2XYT medium containing 1 ⁇ 0 ⁇ g / m1 of ampicillin and 50 ⁇ g / m1 of kanamycin, and cultured overnight at 37 ° C.
- a single-chain antibody-displayed phage was amplified and produced in a medium (phage rescue).
- the amplified phage was recovered again by polyethylene glycol precipitation. Concentration and reinfection by biopanning and amplification by phage rescue were repeated 3 to 5 times.
- a phage clone considered to be sufficiently enriched was infected with E. coli TG1 and plated on agar plates. (: Overnight and cultured in a single mouth. Six clones were randomly selected from a single colony of TG1 for each screening condition, phagemid was prepared by a conventional method, and this was used as a type II BigDye Terminator.
- a sequencing reaction was performed using the Cycle Sequencing Ready Reaction Kit v3.0 (Applied Biosystems) Soil Genetic analyzer ABI PRISM 310 Genetic analyzer (Applied Biosystems) was used to analyze the base sequence and analyze four types of V H chain mutations. Introductory material (DX 3860HL- M # 5, D x 3860 L H- M # 1, Dx 3860
- LH-M # 2, Dx3860 LH—M # 3 were obtained.
- the amino acid sequences of these VH chain variants are shown in FIG. 11 and SEQ ID NOs: 64-67.
- WT DX3860 wild type VH
- 1-2 amino acid mutations were found.
- the mutation site was not specified in the CDR site, but was also found in the framework.
- a large amount of a recombinant antibody recognizing 2, 3, 4, 7, 8-PeCDF can be produced.
- the recombinant antibody produced in this way is less expensive than the parent monoclonal antibody and can be used to immunologically capture 2,3,4,7,8-Pe CDF. It can be applied to
- the use of mutated DNA allows the use of recombinant antibodies having more advantageous properties, such as recombinant antibodies with improved affinity for 2, 3, 4, 7, 8-Pe CDF, and stability. It is possible to produce recombinant antibodies and the like with improved quality, and it is also possible to overcome the problems of natural antibody proteins that are biological components
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/550,951 US7381798B2 (en) | 2003-03-28 | 2004-03-26 | Recombinant antibody recognizing dioxin and gene encoding the antibody |
EP04723765A EP1616885B1 (en) | 2003-03-28 | 2004-03-26 | Recombinant antibody recognizing dioxin and gene encoding the antibody |
JP2005504305A JP4077481B2 (ja) | 2003-03-28 | 2004-03-26 | ダイオキシンを認識する組換抗体および該抗体をコードする遺伝子 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-091663 | 2003-03-28 | ||
JP2003091663 | 2003-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087764A1 true WO2004087764A1 (ja) | 2004-10-14 |
Family
ID=33127288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004355 WO2004087764A1 (ja) | 2003-03-28 | 2004-03-26 | ダイオキシンを認識する組換抗体および該抗体をコードする遺伝子 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7381798B2 (ja) |
EP (1) | EP1616885B1 (ja) |
JP (1) | JP4077481B2 (ja) |
WO (1) | WO2004087764A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1307301C (zh) * | 2005-08-23 | 2007-03-28 | 中国科学院武汉病毒研究所 | 一种检测二恶英的单链抗体方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0818228D0 (en) * | 2008-10-06 | 2008-11-12 | Avecia Biolog Ltd | Purification process |
EP3262411B1 (en) | 2015-02-25 | 2022-04-06 | Vanderbilt University | Antibody-mediated neutralization of marburg virus |
WO2020010235A1 (en) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002119279A (ja) * | 2000-10-16 | 2002-04-23 | Food & Drug Safety Center | ダイオキシンに対するモノクローナル抗体及びその用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4798807A (en) * | 1986-06-24 | 1989-01-17 | The Regents Of The University Of California | Monoclonal antibodies and method for detecting dioxins and dibenzofurans |
FI890341A (fi) * | 1988-01-26 | 1989-07-27 | Hoechst Ag | Foerfarande foer immunodiagnostisk bestaemning av polyhalogenerade, plana, polycykliska, aromatiska kolvaeten. |
JP2002228660A (ja) | 2001-02-05 | 2002-08-14 | Enbiotec Laboratories:Kk | ダイオキシン類の検出方法 |
JP2002340882A (ja) | 2001-03-12 | 2002-11-27 | Osaka Gas Co Ltd | ダイオキシン類の測定装置及び測定方法 |
-
2004
- 2004-03-26 EP EP04723765A patent/EP1616885B1/en not_active Expired - Lifetime
- 2004-03-26 WO PCT/JP2004/004355 patent/WO2004087764A1/ja active Application Filing
- 2004-03-26 US US10/550,951 patent/US7381798B2/en active Active
- 2004-03-26 JP JP2005504305A patent/JP4077481B2/ja not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002119279A (ja) * | 2000-10-16 | 2002-04-23 | Food & Drug Safety Center | ダイオキシンに対するモノクローナル抗体及びその用途 |
Non-Patent Citations (2)
Title |
---|
OMURA NAOYA ET AL.: "Dioxin-rui no jinsoku kan'i sokutei men'eki sokutei (immunoassay)-ho", ENVIRONMENTAL MANAGEMENT, vol. 39, no. 3, 10 March 2003 (2003-03-10), pages 251 - 256, XP002982521 * |
STANKER L.H. ET AL.: "Monoclonal antibodies for dioxin: antibody characterization nad assay development", TOXICOLOGY, vol. 45, no. 3, 1987, pages 229 - 243, XP001189336 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1307301C (zh) * | 2005-08-23 | 2007-03-28 | 中国科学院武汉病毒研究所 | 一种检测二恶英的单链抗体方法 |
Also Published As
Publication number | Publication date |
---|---|
US20060269977A1 (en) | 2006-11-30 |
JPWO2004087764A1 (ja) | 2006-06-29 |
EP1616885A1 (en) | 2006-01-18 |
US7381798B2 (en) | 2008-06-03 |
EP1616885A4 (en) | 2006-07-26 |
EP1616885B1 (en) | 2012-10-10 |
JP4077481B2 (ja) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8148085B2 (en) | Donor specific antibody libraries | |
Yamanaka et al. | Chicken monoclonal antibody isolated by a phage display system. | |
US6818748B2 (en) | Cloning, expression, sequencing, and functional enhancement of monoclonal ScFv antibody against Venezuelan equine encephalitis virus (VEE) | |
CN112794899B (zh) | 一种抗新型冠状病毒的全人源单克隆中和抗体及其应用 | |
Singh et al. | Construction of a single-chain variable-fragment antibody against the superantigen staphylococcal enterotoxin B | |
Deng et al. | Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system | |
EP3650465A1 (en) | Novel populations of polypeptides having a triple-helical structure | |
JPH11127861A (ja) | C型肝炎ウイルス由来のセリンプロテアーゼに対する中和抗体部分ペプチド | |
KR101631054B1 (ko) | 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 | |
EP2121019A1 (en) | A new immunoglobulin against helicobacter pylori | |
EP1457559A1 (en) | ARTIFICIAL ANTIBODY LIBRARY WITH SUPER−REPERTORY | |
WO2004087764A1 (ja) | ダイオキシンを認識する組換抗体および該抗体をコードする遺伝子 | |
US20090215092A1 (en) | Antibodies for Anthrax | |
US8507655B2 (en) | Antibody against anthrax toxins | |
Link et al. | Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation | |
Nishi et al. | Preparation and characterization of monoclonal and recombinant antibodies specific to the insecticide malathion | |
Pokorny et al. | Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies | |
EP0915158A2 (en) | Improvements in or relating to detection of salmonella | |
JPH10507341A (ja) | ファージ技術を用いる触媒性抗体の単離および産生 | |
Ravn et al. | Identification of phage antibodies toward the Werner protein by selection on Western blots | |
CN114437225B (zh) | 一种抗沙丁胺醇和/或克伦特罗单克隆抗体和应用 | |
US7615218B2 (en) | Methods for determining and lowering caffeine concentration in fluids | |
JP2007534759A (ja) | 設計デコイタンパク質を用いる溶液相バイオパニング方法 | |
WO2013021277A1 (en) | Recombinant ant-bovine iga antibody and uses thereof | |
Fu et al. | Isolation of single chain variable fragments against six esters of pyrethrins by subtractive phage display |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005504305 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004723765 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004723765 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006269977 Country of ref document: US Ref document number: 10550951 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10550951 Country of ref document: US |